Patent ID: 11890293
Assignee: GLYCOM A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 6:
7. A method comprising:
selecting an effective amount of one to nine human milk oligosaccharides (HMOs) selected from:
fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I);
non-fucosylated HMO selected from lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT), 3′, 6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL) and mixtures thereof, in a total daily dosage of HMOs from about 3 g to about 10 g that is effective to increase Bifidobacterium adolescentis in the gut microbiota of a non-infant human during an initial treatment period; and

increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of a non-infant patient and improving in the non-infant patient at least one condition selected from reduced metabolic endotoxemia, an improved level of a glucagon-like peptide, and a reduction in an inflammatory marker associated with a metabolic disorder by providing the total daily dosage of the selected one or more HMOs consumed by the non-infant patient during the initial treatment period.